Product Center
Ab&B Bio-Tech Co., Ltd. has won the Golden Bull Award for 2025 Hong Kong Stock Exchange Listed Companies!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-11-08
- Views:
(Summary description)On November 8th, the 2025 Outstanding Hong Kong Listed Company Golden Bull Award was announced in Xiamen. Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") has won the 2025 Growth Value Golden Bull Award for its outstanding achievements and outstanding performance in Hong Kong stock market value.
Ab&B Bio-Tech Co., Ltd. has won the Golden Bull Award for 2025 Hong Kong Stock Exchange Listed Companies!
(Summary description)On November 8th, the 2025 Outstanding Hong Kong Listed Company Golden Bull Award was announced in Xiamen. Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") has won the 2025 Growth Value Golden Bull Award for its outstanding achievements and outstanding performance in Hong Kong stock market value.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-11-08 08:59
- Views:
On November 8th, the 2025 Outstanding Hong Kong Listed Company Golden Bull Award was announced in Xiamen. Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") has won the 2025 Growth Value Golden Bull Award for its outstanding achievements and outstanding performance in Hong Kong stock market value.
The "Listed Company (Hong Kong Stock) Golden Bull Award" hosted by China Securities Journal is a highly credible and authoritative award in the Chinese capital market, aimed at recognizing outstanding Hong Kong listed companies with standardized governance, performance growth, and positive returns to shareholders and society. With a rigorous, scientific, and transparent evaluation system, this award has become one of the most credible professional exchange platforms in China's capital market, effectively promoting the positive interaction between industry and capital.
The "Growth Value Taurus Award" won by the company this time belongs to the "Growth and Innovation Category". The selection process of this award focuses on innovative breakthroughs in cutting-edge technology fields such as artificial intelligence, new energy, and biomedicine. It aims to recognize Hong Kong listed companies that have demonstrated strong comprehensive strength and forward-looking development strategies in high-quality development and industrial transformation. At the same time, it also encourages companies to not only have a fast growth rate, but also to have sustained and stable value creation capabilities.
At the conference, the chairman and general manager of the company, An Youcai, was invited to participate in the roundtable forum on "New Quality Productivity Engine: How AI Reshaps the Value Growth Curve of Hong Kong Listed Companies". We shared the latest developments in our respective fields with numerous industry experts, broke down industry barriers, and conducted cutting-edge thinking collisions and experience exchanges on the application of AI technology and scientific empowerment of the full chain operation of Ab&B Bio's research, production, and sales.
After the meeting, Mr. An accepted an exclusive interview with a reporter from China Securities Journal, focusing on the market performance and future development ideas of Ab&B Bio after its listing on the Hong Kong stock market. He talked about the core logic of Ab&B Bio's highly recognized market after its listing on the Hong Kong stock market, as well as how the company will embrace the wave of change with innovation driven, quality leading, management efficiency improving, and overseas expansion as its strategic axis in the future, and continuously strive towards the vision of enabling China to use global innovative vaccines and the world to use high-quality Chinese vaccines!
Relevant information
-
Ab&B Bio-Tech Co., Ltd. collaborates with Walvax Biotechnology Co., Ltd. to seamlessly connect the third-generation subunit influenza vaccine and embark on a new journey of going globalOn March 13, 2026, Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") and Walvax Biotechnology Co., Ltd. (hereinafter referred to as "Walvax") officially signed a strategic cooperation agreement for the overseas market of influenza virus subunit vaccines in Taizhou. Both parties announced that they will jointly promote the development of the influenza virus subunit vaccine independently developed by Ab&B Bio and set sail to the sea. This is not only a milestone moment for Chinese vaccine companies to cooperate and build a healthy industry ecosystem, but also signifies that China will bring safer and more effective solutions to the global influenza prevention and control field. - Monkeypox mRNA Vaccine Secures FDA Clinical Approval, Trivalent Influenza Virus Subunit Vaccine Wins First Bid in Shanxi 03-04
- Announcement of Pre increase in Performance for 2025 Released 02-26
- Ab&B Bio-Tech Co., Ltd. has been included in the Hang Seng Composite Index, and its recognition in the capital market continues to increase 02-16
- The study on pregnant women receiving quadrivalent influenza virus subunit vaccine has successfully completed key enrollment 02-10
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
